Profile data is unavailable for this security.
About the company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
- Revenue in USD (TTM)0.00
- Net income in USD-147.03m
- Incorporated2012
- Employees56.00
- LocationAtea Pharmaceuticals Inc225 Franklin Street, Suite 2100BOSTON 02110United StatesUSA
- Phone+1 (857) 204-8109
- Fax+1 (302) 655-5049
- Websitehttps://ateapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 284.70m | 60.00 | -- | -- | -- | 56.33 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Rezolute Inc | 0.00 | -77.18m | 290.24m | 71.00 | -- | 1.94 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -54.73 | -47.11 | -58.50 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 293.50m | 33.00 | -- | 2.40 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Prenetics Global Ltd | 66.32m | -40.67m | 297.91m | 285.00 | -- | 1.48 | -- | 4.49 | -3.10 | -3.54 | 5.01 | 14.26 | 0.3068 | 4.83 | 17.70 | 232,698.60 | -20.40 | -60.40 | -25.34 | -81.53 | 48.01 | 40.86 | -66.49 | -385.99 | 2.51 | -3.83 | 0.0129 | -- | 40.83 | 27.10 | 14.76 | -- | 23.29 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 303.50m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 306.69m | 275.00 | -- | 0.0334 | -- | 1.35 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -56.17m | 308.00m | 17.00 | -- | 14.73 | -- | -- | -1.80 | -1.80 | 0.00 | 0.2852 | 0.00 | -- | -- | 0.00 | -159.13 | -77.37 | -195.99 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 316.76m | 38.00 | -- | 3.95 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 319.22m | 112.00 | -- | -- | -- | 13.02 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Immuneering Corp | 0.00 | -62.50m | 319.62m | 54.00 | -- | 1.38 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| PepGen Inc | 0.00 | -93.56m | 321.05m | 81.00 | -- | 1.97 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 323.44m | 56.00 | -- | 1.02 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -43.19m | 334.51m | 9.00 | -- | 6.79 | -- | -- | -0.7217 | -0.7217 | 0.00 | 0.8185 | 0.00 | -- | -- | 0.00 | -44.27 | -34.06 | -57.79 | -38.07 | -- | -- | -- | -- | -- | -- | 0.2359 | -- | -- | -- | -48.77 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 334.57m | 28.00 | -- | 1.89 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 334.82m | 18.00 | -- | 25.66 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 346.31m | 299.00 | -- | 1.10 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
Data as of Feb 10 2026. Currency figures normalised to Atea Pharmaceuticals Inc's reporting currency: US Dollar USD
45.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2025 | 7.49m | 9.59% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.21m | 7.95% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.82m | 7.45% |
| Tang Capital Management LLCas of 30 Sep 2025 | 4.83m | 6.18% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.75m | 4.80% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.90m | 2.43% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.78m | 2.28% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 1.45m | 1.86% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 1.23m | 1.57% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 969.77k | 1.24% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
